Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ASH: "Bexxar" Regimen Induces Complete Response in Patients with Follicular Non-Hodgkin's Lymphoma By Charlene Laino SAN DIEGO, CA -- December 18, 2003 -- The so-called "Bexxar" regimen of tositumomab and iodine 131 I tositumomab produces long-term responses in patients with lymphoma, including those with heavily pre-treated follicular non-Hodgkin's lymphoma who have had multiple relapses, according to a new study. These results were presented here on December 7th at the 45th Annual Meeting of the American Society of Hematology by Morton Coleman, MD, director, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and the New York Presbyterian Hospital, New York, United States. The regimen is already changing clinical practice, noted Dr. Coleman. Based on prior studies, the regimen was recently approved for the treatment of patients with CD20-positive, follicular non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to rituximab and who have relapsed following chemotherapy. The goal of the new study was to determine the percentage of patients that can be expected to achieve long-term responses, Dr. Coleman said. The study enrolled 230 patients, with a median age of 52 years, almost all of whom had Stage III/IV disease. At 12 months, 24% of subjects had a durable complete response, defined as complete resolution of radiological abnormalities and disappearance of signs and symptoms related to the disease for at least 12 months. Three-fourths of the patients were still in complete remission after a median follow-up of nearly 5 years, Dr. Coleman said. Patients who relapsed after treatment, or who were refractory to rituximab therapy, and patients who had not received rituximab in the past were equally likely to experience a durable complete response, the study showed. [Study Title: The BEXXAR Therapeutic Regimen (Tositumomab and Iodine 131 I Tositumomab) Produced Durable Complete Remissions in Heavily Pretreated Patients with Non-Hodgkins Lymphoma (NHL), Rituximab-Relapsed/Refractory Disease, and Rituximab-Naive Disease. Abstract 89] E-mail this page to a friend or colleague! To print, use this version